Stock Events

Stock Events

Argenica Therapeutics Limited 

$0
6
+$0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

4MarExpected
Q4 2023
Q2 2024
Q4 2024
-0.01
0.32
0.66
0.99
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-3.68MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGNTF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap25.38B
Lilly(Eli) &
LLY
Mkt Cap840.84B
Eli Lilly and Company has extensive research in neurodegenerative diseases and stroke, overlapping with Argenica's therapeutic areas.
Novartis
NVS
Mkt Cap297.35B
Novartis AG has a significant presence in neuroscience and treatments for neurological conditions, competing in the same therapeutic space as Argenica.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. is involved in developing treatments for neurological disorders, including stroke, which is a direct competition to Argenica's research focus.
Roche
RHHBY
Mkt Cap322.3B
Roche Holding AG has a strong portfolio in neurology and brain health, making it a competitor in the neurological treatment market.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca PLC has initiatives in developing therapies for stroke and neurological disorders, areas where Argenica is also active.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. works on neuroprotective drugs and treatments for brain injuries, competing with Argenica's stroke recovery solutions.
GSK
GSK
Mkt Cap116.3B
GlaxoSmithKline plc invests in neurological health, including stroke recovery and prevention, aligning as a competitor to Argenica.
Abbott Laboratories
ABT
Mkt Cap174.29B
Abbott Laboratories offers various medical devices and pharmaceuticals for neurological conditions, indirectly competing with Argenica's therapeutic approach.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson engages in the development of treatments for neurodegenerative diseases, overlapping with Argenica's focus areas.

About

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Show more...
CEO
Country
Australia
ISIN
AU0000150328

Listings

AU
AU
AGN.AU

0 Comments

Share your thoughts

FAQ

What is Argenica Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Argenica Therapeutics Limited stocks are traded under the ticker AGNTF.
What is Argenica Therapeutics Limited revenue for the last year?▼
Argenica Therapeutics Limited revenue for the last year amounts to 0 USD.
What is Argenica Therapeutics Limited net income for the last year?▼
AGNTF net income for the last year is -3.68M USD.
In which sector is Argenica Therapeutics Limited located?▼
Argenica Therapeutics Limited operates in the Technology sector.
When did Argenica Therapeutics Limited complete a stock split?▼
Argenica Therapeutics Limited has not had any recent stock splits.